Compare CABA & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CABA | GNE |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 359.1M |
| IPO Year | 2019 | 2011 |
| Metric | CABA | GNE |
|---|---|---|
| Price | $3.67 | $13.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $14.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 5.1M | 58.6K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | 10.26 | ★ 95.65 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $425,202,000.00 |
| Revenue This Year | N/A | $17.49 |
| Revenue Next Year | N/A | $7.07 |
| P/E Ratio | ★ N/A | $126.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $12.69 |
| 52 Week High | $4.23 | $28.47 |
| Indicator | CABA | GNE |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 48.21 |
| Support Level | $2.11 | $13.41 |
| Resistance Level | $3.73 | $14.85 |
| Average True Range (ATR) | 0.24 | 0.47 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 61.41 | 64.57 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.